| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Nxstage Hopes $79 Million Acquisition Brings Profitability
Posted on 06/06/2007 08:10:42 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel
NxStage Medical (NXTM), a Lawrence, MA, company that makes dialysis systems, plans to acquire the private company whose cartridges are used in its NxStage System One portable kidney dialysis machine. NxStage will pay $78.7 million for Seattle-based Medisystems, which, in addition to the cartridges used in the System One machine, makes hemodialysis blood tubing sets, A.V. fistula needles, and other ancillary hemodialysis disposables. NxStage is banking on the addition of Medisystems’ assets to bring the company to profitability by the end of 2008.
Medisystems’ president and CEO, David Utterberg, stands to profit heftily from the deal. He owns all of the outstanding shares of his company, which in 2006 recorded revenues of $65.5 million, and is a member of NxStage’s board. His 7% ownership of NxStage common stock would go up to about 23% as a result of this merger. Utterberg will serve in a consulting capacity to the combined company for two years and will remain a NxStage director.
Source: Med Tech Sentinel
BioHealth Investor.com
______________________
Med Tech Sentinel
NxStage Medical (NXTM), a Lawrence, MA, company that makes dialysis systems, plans to acquire the private company whose cartridges are used in its NxStage System One portable kidney dialysis machine. NxStage will pay $78.7 million for Seattle-based Medisystems, which, in addition to the cartridges used in the System One machine, makes hemodialysis blood tubing sets, A.V. fistula needles, and other ancillary hemodialysis disposables. NxStage is banking on the addition of Medisystems’ assets to bring the company to profitability by the end of 2008.
Medisystems’ president and CEO, David Utterberg, stands to profit heftily from the deal. He owns all of the outstanding shares of his company, which in 2006 recorded revenues of $65.5 million, and is a member of NxStage’s board. His 7% ownership of NxStage common stock would go up to about 23% as a result of this merger. Utterberg will serve in a consulting capacity to the combined company for two years and will remain a NxStage director.
Source: Med Tech Sentinel
BioHealth Investor.com
______________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Newmark's Door
- The Family CEO
- Ludwig von Mises Institute
- Credit Bloggers
- Wishing Wealth
- Financial Skeptic
Examples
Boucher On The Big Picture - Thu Aug 14, 2008 04:54PM
Watch Interest Rates Next For Clue as to When Downside R [read more]
Watch Interest Rates Next For Clue as to When Downside R [read more]
Morpheus Trading - Thu Aug 14, 2008 07:54AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Editorial Spotlight - Fri Aug 15, 2008 10:33AM
They say the most dangerous enemy is the one you don’ [read more]
They say the most dangerous enemy is the one you don’ [read more]
<< My Home | TheMoneyBlogs Home